Akèy › Mesotelyom › Ohio
Etid klinik pou Mesotelyom nan Ohio
9 etid pou Mesotelyom ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
SW-682 in Advanced Solid Tumors
- University Hospital of Cleveland, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06251310Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04981119Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06566079Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Ohio State University, Columbus
Ap rekriteFaz 1/2
Laj 18 a 90 · Tout sèks · Mizajou Jul 6, 2026 · NCT06710756Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 12, 2026 · NCT06051695Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- The Ohio State University Wexner Medical Center, Columbus
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Mar 9, 2026 · NCT04792463VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Taylor Cancer Research Center (site 204), Maumee
Ap rekriteFaz 1/2
Laj 18 a 80 · Tout sèks · Mizajou Dec 11, 2025 · NCT03556228Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.